Ultragenyx製藥 RARE 深 滬
已收盤 12-19 16:00:00 美东时间
33.50
+0.660
+2.01%
華盛通- 最 高34.03
- 今 開32.84
- 成交量 249.72万股
- 最 低 32.65
- 昨 收 32.84
- 總市值 32.32亿
- 52周最高 46.50
- 市盈率 靜 --
- 換手率 2.59%
- 52周最低 25.81
- 委 比 35.95%
- 總股本 9647.76万
- 歷史最高 179.647
- 量 比 1.55
- 振 幅 4.20%
- 歷史最低 25.81
- 每 手 1
- 風險率 5.05%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
On December 19, 2025, Ultragenyx Pharmaceutical Inc. announced the grant of 13,144 restricted stock units to nine newly hired non-executive officers. The awards, approved by the company’s compensation committee, were granted under the Ultragenyx Employment Inducement Plan on December 17, 2025, as an inducement for new employees. The restricted stock units vest over four years, with 25% of the shares vesting annually, contingent on continuous empl...
12-19 21:30
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
11-25 10:27
Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $50
Barclays analyst Gena Wang maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and lowers the price target from $81 to $50.
11-24 22:42
Ultragenyx to Participate in Investor Conferences in December
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced its participation in two investor conferences in Miami, FL: Citi's 2025 Global Healthcare Conference on December 2, 2025, and the 8th Annual Evercore ISI Healthcare Conference on December 3, 2025. Both events will feature Eric Crombez, M.D., Chief Medical Officer, in fireside chats. Live and archived webcasts will be available on the company’s website. Ultragenyx focuses on developing therap...
11-24 21:30
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical Inc.授予了12名新聘非高管员工总计18,180股限制性股票单位，这些股票分四年解锁，每年解锁25%，并需符合纳斯达克上市规则。公司致力于开发罕见及超罕见疾病新型疗法，由经验丰富的管理团队领导，专注于高效药物开发以满足未竟医疗需求。 Ultragenyx Pharmaceutical Inc.授予12位新入职非高管员工18,180股限制性股票单位，股票按四年计划解锁，每年解锁25%，需符合纳斯达克规则。公司专注罕见病治疗，目标是开发高效药物以满足高未竟医疗需求。
11-21 21:30
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
11-06 09:55
Earnings Scheduled For November 4, 2025
Companies Reporting Before The Bell • Sequans Communications (NYSE:SQNS) is lik...
11-04 19:12
Kiora Pharmaceuticals Joins Global Genes' RARE-X Vision Consortium, A Corporate-Nonprofit Initiative Aimed At Advancing Research For Rare Ocular Disorders
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) and Global Genes today announced that Kiora has joined Global Genes' RARE-X Vision Consortium, a corporate-nonprofit partnership with a mission to promote and facilitate
10-30 21:07
Ultragenyx Begins Dosing in Aurora Study for Angelman Syndrome
Ultragenyx Pharmaceutical ( ($RARE) ) just unveiled an update. On October 30, 2...
10-30 20:55
What to Expect from Kiniksa Pharmaceuticals's Earnings
Kiniksa Pharmaceuticals (NASDAQ:KNSA) is preparing to release its quarterly ear...
10-28 03:01
